Bumetanide for Health & Longevity - Quick Reference Sheet

Bumetanide for Health & Longevity

Created on 10/11/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Bumetanide, a strong prescription medication that makes the kidneys flush out salt and water, is proven for clearing fluid buildup in heart, kidney, and liver disease. Protection of the aging brain against Alzheimer's disease is unproven, with mixed health-record findings and no human prevention trial. For health-focused adults without fluid buildup, low potassium, dehydration, and dizziness on standing are frequent, predictable downsides, manageable with blood tests and careful dosing. (Full Review)

Protocol

No established longevity protocol
Brain-directed use investigational
No guideline or practitioner protocol for healthy adults; Alzheimer's trial doses undisclosed
Approved edema regimen
0.5–2 mg orally once daily
Further doses at 4–5-hour intervals up to 10 mg/day; intermittent schedules preferred; label advises low-end start in older adults
Time of day
Morning dosing
Avoids nighttime urination
Time to effect
Fluid clearance (diuresis)
30–60 minutes
Largely complete within 4 hours at 1–2 mg
Blood pressure
6 weeks
Effects measured after 6 weeks
Cognitive effect
Unknown
Trials running 6 months

Benefits

Contraindications
  • Anuria (no urine production)
  • Hepatic coma (coma from liver failure)
  • Severe electrolyte depletion (until corrected)
  • Known hypersensitivity to bumetanide (caution with sulfonamide, or sulfa, allergy)
  • Progressive kidney disease with a marked rise in BUN (blood urea nitrogen) or creatinine, or oliguria (low urine output), during treatment
  • People taking lithium
  • Pregnancy (only if benefit justifies fetal risk) and breastfeeding
  • Competitive athletes under anti-doping rules (prohibited at all times)
Key Interactions
  • Aminoglycosides and other ear-toxic drugs (gentamicin, tobramycin, cisplatin): avoid with intravenous bumetanide except in life-threatening situations
  • Nephrotoxic (kidney-toxic) drugs (amphotericin B, vancomycin, aminoglycosides); Probenecid; Indomethacin: avoid
  • Blood-pressure drugs (lisinopril, losartan, amlodipine); Digoxin; SGLT2 inhibitors (dapagliflozin, empagliflozin; drugs that make the kidney excrete glucose); Low-salt diets: monitor
  • Thiazide diuretics (hydrochlorothiazide, metolazone): caution
  • QT-prolonging drugs (sotalol, dofetilide; drugs that delay heart electrical recovery); NSAIDs (ibuprofen, naproxen, high-dose aspirin); Licorice root (glycyrrhizin): caution (theoretical)
  • Corticosteroids (prednisone, hydrocortisone); Stimulant laxatives (bisacodyl, senna); Diuretic herbs and caffeine (dandelion leaf, high-dose caffeine); Blood-pressure-lowering supplements (garlic extract, hibiscus); Sauna, heat exposure, prolonged endurance exercise: monitor (theoretical)
  • Potassium and magnesium supplements: beneficial; caution if also taking potassium-sparing drugs (spironolactone)

Risk & Side Effects

  • High: Low potassium and other electrolyte losses; fluid depletion and low blood pressure on standing
  • Medium: Raised uric acid; bone mineral density loss
  • Low: Kidney function decline; hearing damage; unfavorable glucose and lipid shifts; serious skin reactions; low platelet count
  • Speculative: Memory worsening without the APOE4 gene variant

Monitoring

Marker Target Why
Serum potassium 3.5–5.0 mmol/L (standard reference range) Safety check: low potassium stops or changes use
Serum sodium 135–145 mmol/L (standard reference range) Safety check: low sodium changes dosing
Serum magnesium 1.7–2.2 mg/dL (standard reference range) Safety check: low magnesium makes low potassium hard to correct
Creatinine and eGFR (estimated kidney filtration rate) Creatinine 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women (standard reference range); eGFR: no established target, track change from own baseline Safety check: a marked rise stops use
Serum uric acid 3.5–7.2 mg/dL men, 2.6–6.0 mg/dL women (standard reference range) Safety check; expected to rise
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: high blood sugar changes use
Platelet count 150–450 × 10⁹/L (standard reference range) Safety check: low platelet count stops use
Seated and standing blood pressure No established target; track change from own baseline Expected to fall; safety check for drops on standing
Body weight No established target; track change from own baseline Expected to fall with fluid loss; rapid loss signals dehydration
Audiogram (hearing test) No established target; compare with own baseline Safety check: hearing loss stops use

Cadence: Baseline panel; electrolytes and creatinine 1–2 weeks after starting or any dose change, at 4–6 weeks, then every 3 months; uric acid and glucose at 3 months, then every 6–12 months; home blood pressure and weight weekly in month 1; platelets every 6–12 months; repeat audiogram if hearing changes.

Qualitative Assessment

  • Thirst, dry mouth, and urine color as signs of dehydration
  • Dizziness or light-headedness on standing
  • Muscle cramps or weakness suggesting low potassium or magnesium
  • Nighttime urination and sleep continuity
  • Ringing in the ears or hearing change
  • Memory, word-finding, and mental clarity in brain-directed use